Introduction
============

Esophageal cancer (EC) is the third most common cause of cancer-related death in China [@B1]. More than 50% of newly diagnosed EC cases are classified as locally advanced disease. Concurrent chemoradiotherapy (CRT) is recommended as the standard treatment for locally advanced unresectable EC [@B2]. However, the prognosis for EC patients after definitive CRT remains poor, with local recurrence and distant metastasis being the major patterns of failure: the 5-year overall survival (OS) rate remains less than 20% [@B3].

In theory, the addition of induction chemotherapy (IC) before definitive CRT has the potential to achieve benefit in terms of a better response rate, early eradication of micrometastases, increased tumor radiosensitivity because of tumor shrinkage, and even overall survival [@B4]. Currently, several lines of evidence support the addition of IC to CRT in locally advanced esophageal squamous cell carcinoma (ESCC). In trial INT 0122, 38 patients with clinical Stage T1-4N0-1M0 ESCC received IC followed by CRT based on cisplatin combined with 5-fluorouracil (the PF regimen) were eligible, with 47% achieving a complete response (CR) and the median survival was 20 months. After IC, 90% symptoms of dysphagia improved significantly [@B5]. Michel *et al.* reported that induction cisplatin-irinotecan followed by CRT without surgery for stage I-III esophageal cancer resulted in a complete clinical response rate of 58.1% and overall survival rates at 1 and 2 years of 62.8% and 27.9%, respectively, in a multicenter phase II FFCD trial [@B6]. Akinori *et al.* found that IC responder patients showed an improved survival rate and no increase in severe toxicity in T4M0 esophageal cancer [@B7]. Moreover, Hironaga et al. conducted a prospective, multicenter phase I/II study and found that the 3-year survival rate was higher in the IC group compared with that in the control cohort [@B8].

The value of adding IC before definitive CRT in ESCC is still unclear because of the lack of prospective randomized trials. Thus we analyzed retrospectively the data of 267 patients receiving IC plus CRT or CRT alone, using the matched case-control method to compare the clinical outcomes. This study provided valuable effect assessment and evidence for future randomized controlled trials.

Patients and Methods
====================

Patients
--------

Between January 2002 and December 2015, 408 consecutive EC patients who underwent definitive CRT at the authors\' institution were reviewed retrospectively. Criteria for inclusion were as follows: (1) histologically confirmed thoracic ESCC; (2) Eastern Cooperative Oncology Group performance status (PS) ≤ 2; (3) no distant organ metastasis; (4) no anticancer therapy history; (5) no concomitant or previous malignancy history; (6) unresectable or inoperable; (7) chemotherapy regimen comprising docetaxel and cisplatin (DP); (8) multidisciplinary evaluation before initiation of treatment; and (9) complete and retrievable clinical data. Overall, 85 patients fulfilling these criteria, who received IC before CRT, were defined as the study group. These patients were matched 1:1 to randomly selected patients who received CRT alone during the same study period, defined as the control group. The two groups were matched in a blinded fashion to the clinical outcomes, in accordance with the most relevant prognostic factors, including age (within 5 years), gender, PS score (0 *vs*. 1-2), tumor location (upper *vs*. middle *vs*. lower third), tumor length (within 3 cm), and pretreatment TNM stage (III vs. IV). This study was approved by the institutional review board.

Pretreatment Work-up
--------------------

Pretreatment work-up included physical examination, standard laboratory tests, a barium swallow test, endoscopy with biopsies, endoscopic ultrasonography (EUS), pulmonary function test, and thoracoabdominal computed tomography (CT). Bone scans and positron emission tomography (PET) were performed selectively. Staging was performed according to the sixth TNM staging system of the American Joint Committee on Cancer [@B9].

Treatment
---------

All patients received concurrent chemotherapy with a three-weekly schedule of docetaxel (60 mg/m^2^ on day 1) plus cisplatin (60-80 mg/m^2^ on day 1) or weekly schedule of docetaxel (25 mg/m^2^ on day 1) plus cisplatin (25 mg/m^2^ on day 1) for 5-7 weeks. For the IC group, patients were treated with two cycles of docetaxel (75 mg/m^2^ on day 1) plus cisplatin (75 mg/m^2^ on day 1) before CRT [@B10]. Dose adjustment was performed in the following chemotherapy cycle.

Radiation therapy was delivered by three-dimensional conformal radiotherapy or intensity-modulated radiotherapy with 6-8 MV X-ray. The gross tumor volume (GTV) was defined as the primary tumor and positive lymph nodes. The clinical target volume (CTV) comprised the GTV with a 3-cm margin in the cephalad and caudal directions, and a radial margin of 0.5-1.0 cm. CTV also included the regional lymphatic regions. The planning target volume included the CTV with a 1-cm margin in all directions. A standard prescription dose of 60 Gy was delivered in 1.8-2.0 Gy fractions over 6-7 weeks.

Toxicity and follow-up
----------------------

The toxicities of CRT were graded according to the National Cancer Institute Common Toxicity Criteria (version 3.0). Patients were followed up via physical examination, chest and abdominal CT, endoscopy with biopsies, and barium esophagography at 3-monthly intervals for the first two years, and every 6 months thereafter. The data were updated in December 2016.

Statistical Analysis
--------------------

The clinical tumor response after IC was assessed by barium swallow and CT. CR was defined as no unequivocal soft tissue mass in the local region and all regional lymph nodes were less than 1.0 cm in the short axis. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameters of the target lesions for over four weeks. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of the target lesions, or the appearance of one or more new lesions. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Categorical variables were compared using the chi-square test or Fisher\'s exact test. The primary endpoint was OS, and the secondary endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). OS was calculated from the diagnosis of ESCC until death or last follow-up. PFS was defined as the duration until locoregional recurrence or distant progression, last follow-up, or death. DMFS was defined as the time from treatment to the first distant metastasis, and LRFS was defined as the time from treatment to the first locoregional relapse. The Kaplan-Meier method was used to estimate the survival curves; the differences were compared using the log-rank test. A multivariate analysis using Cox proportional hazards survival regression analyses with stepwise regression (forward selection) for the whole cohort was conducted to evaluate the influence of the clinical variables on OS and PFS. All statistical analyses were performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) and Stata 12.0. A two-sided *P*-value \< 0.05 was considered statistically significant.

Results
=======

Patient and Tumor Characteristics
---------------------------------

The baseline characteristics of the 170 patients are listed in Table [1](#T1){ref-type="table"}. Within the whole series, the median age was 60 years (range, 47-70 years), and the male to female ratio was 5.5:1. The median length of the primary tumor was 6 cm (range, 2.5-13.0 cm), and the majority of tumors were located in the middle third of the esophagus (74.1%). Overall, 28 patients were classified as stage III (16.5%) and 142 as stage IV (83.5%). Forty-four patients were treated with three-dimensional conformal radiotherapy (3DCRT) and 126 received intensity-modulated radiation therapy (IMRT). The median radiation dose was 60 Gy (range, 50-70 Gy) in the whole cohort. Patient and disease-related characteristics were well balanced between the two treatment groups.

Response to induction chemotherapy
----------------------------------

For patients in the IC group, 77 patients (90.6%) had two cycles of IC, three (3.5%) had one cycle, and 5 (5.8%) had three cycles. After IC, CR was obtained in 0 patients (0%), a PR in 43 (50.6%), SD in 32 (37.6%), and PD in 10 patients (11.8%), respectively. The overall response rate (CR+PR) was 50.6%.

Toxicity
--------

The incidences of grade 3-4 toxicities are summarized in Table [2](#T2){ref-type="table"}. Grade 3-4 hematological toxicity occurred in 38.8% of patients receiving IC versus 28.2% of patients who received CRT alone (*P* = 0.317). The IC group had significantly higher proportions of grade 3-4 leucopenia than the CRT group (*P* = 0.048). The most commonly documented treatment-related acute toxicities were skin toxicity, fatigue, nausea, and esophagitis. There were no significant differences in the occurrence of non-hematological toxicities between the two groups. No treatment-related deaths were recorded.

Follow-up and Survival
----------------------

In the original unmatched cohort of 267 patients, the median follow-up time was 26.0 months (8.0-99.0 months) for the IC group and 28.0 months (3.0-121.0 months) for the CRT group, respectively. The median OS for the whole cohort was 24 months (95% confidence interval \[CI\], 18.1-29.9 months), with a 3-year OS rate of 28.2%. In December 2016, 113 (66.5%) patients had died and 57 (33.5%) remained alive in the whole group. A total of 52 (61.2%) patients had died and 33 (38.8%) remained alive in the IC group, whereas, 61 (71.8%) patients had died and 24 (28.2%) remained alive in the CRT group. Among the 170 matched patients, 37 had locoregional recurrence only, 31 had distant metastasis only, 47 had concurrent locoregional and distant failure, and 55 had not developed recurrence. A total of 54 (63.5%) patients had recurrence in the IC group, and 61 (71.8%) in the CRT group. No statistically significant differences were observed between the IC group and the CRT group in terms of the survival rate (*P* = 0.144) and the recurrence rate (*P* = 0.251).

The median OS in the IC group was significantly longer compared with that in the CRT group (26.0 *v*s. 22.0 months), with 3-year OS rates of 30.6% *vs*. 25.9%, respectively (*P* = 0.028, Figure [1](#F1){ref-type="fig"} A). Likewise, the 3-year PFS rate of the IC group was significantly higher than that of the CRT group (24.7% *vs*. 16.5%), with a median PFS of 24.0 *vs*. 16.0 months, respectively (*P* = 0.015, Figure [1](#F1){ref-type="fig"} B).

Patients in the IC group were divided into two subgroups, including 43 IC responders (CR+PR) and 42 non-responders (PD+SD). As shown in Figure [2](#F2){ref-type="fig"}, the IC responders were significantly better compared with the IC non-responders in terms of OS (*P* = 0.002), PFS (*P* = 0.001) and LRFS (*P* = 0.002), but not in DMFS (*P* = 0.116). No statistically significant differences were observed between the IC non-responder group and the CRT alone group in terms of OS (*P* = 0.963), PFS (*P* = 0.923), DMFS (*P* = 0.366), and LRFS (*P* = 0.355).

Prognostic Analysis
-------------------

For the entire group, univariate analysis indicated that sex, smoking, drinking, weight loss before treatment, performance status, primary tumor location, primary tumor length, histologic grade, radiotherapy technique, and CRT regimen did not affect OS significantly (Table [3](#T3){ref-type="table"}). Statistically significant factors or those approaching significance (*P* \< 0.1) in the univariate analysis were subsequently included in the multivariate analysis, which showed that age ≥ 60 (*P* = 0.003) and the addition of IC (*P* = 0.016) were independent prognostic factors that affected survival positively.

Discussion
==========

Although the standard care for locally advanced esophageal cancer is definitive CRT, the long-term outcomes remain limited [@B11]. The efficacy and toxicity of IC before definitive CRT for ESCC patients have not been well documented previously. In the current study, a matched case-control method was used to adjust for differences in the baseline characteristics of the patients and to reduce selection bias, enabling an accurate comparison of the efficacies of these chemotherapy sequences. We found that patients who received IC plus CRT, especially the IC responders, had a significant survival advantage over patients receiving CRT alone.

The evidence supporting administration of IC before neoadjuvant CRT in esophageal cancer is controversial. Heta et al. analyzed retrospectively 119 esophageal cancer patients who underwent IC before neoadjuvant CRT and indicated that the addition of IC did not improve their pathological responses, OS, or DFS [@B12]. Ajani et al performed a prospective phase II randomized trial to compare IC followed by neoadjuvant CRT versus neoadjuvant CRT with oxaliplatin/fluorouracil regimens. However, the addition of IC produced only a non-significant increase in the pathological CR rate and did not prolong the OS [@B13]. In another randomized phase II trial, Doket *et al.* also reported that the addition of IC before neoadjuvant CRT failed to improve the pathological response and survival [@B14]. Above all, the addition of IC to neoadjuvant CRT failed to provide an obvious benefit in esophageal cancer. In contrast, in the present study, the OS in the IC group was significantly more favorable than that in the CRT alone group. There are several possible reasons for the difference. First, the majority of patients were esophageal adenocarcinoma in these studies, which is different from the histology of SCC in our study. Second, there were few patients with T4 or stage IV disease in the previous studies. It has been reported that patients with T4 had an incidence of perforation of 14-23% during CRT. The addition of IC before CRT might reduce the risk of perforation by decreasing the tumor volume before encountering severe esophagitis, which would benefit prolonged survival [@B15], [@B16]. Akinori *et al.* found that IC for T4 esophageal cancer was effective to resolve severe dysphagia [@B7]. Moreover, 90% of the symptoms of dysphagia improved significantly after IC in the trial INT 0122 [@B5]. Therefore, IC might only be of benefit in some high-risk patients, such as ESCC with bulky tumors or stage IV disease.

Michael *et al.* revealed that the clinical tumor response to IC was the single independent prognostic factor for overall survival in patients who received IC followed by CRT, with or without surgery [@B17]. Similarly, Akinori *et al.* documented that the CR rate after CRT and the OS in the IC responder group were significantly better than those in the non-responder group (*P* \< 0.01). Consistently, in our study, we found that the IC responders had significantly better survival at all end-points compared with the IC non-responders. In addition, no statistical differences in survival were observed between the IC non-responder group and the CRT group. Our data suggested that the IC responders might have a better CRT effect, prolonged OS, improved locoregional control, and reduced distant metastasis. Thus, it would be desirable to provide further insights into the potentially important role of distinguishing the IC responders from the whole group, or to identify potential biomarkers that might be beneficial in predicting chemoradiosensitivity and prognosis in ESCC.

Although the classical chemotherapy regimen for esophageal cancer patients is fluorouracil/cisplatin (PF), the prognosis is unsatisfactory [@B18]. Recently, there have been multiple reports about radiotherapy combined with docetaxel-based chemotherapy in esophageal carcinoma. Docetaxel is a taxoid that is derived semi-synthetically from the precursor 10-decacetyl baccatin III, which has a radiation-sensitizing effect in *in vitro* studies [@B19]. A randomized clinical study of 90 ESCC patients undergoing definitive CRT showed that the DP regimen yielded a better overall response rate and OS compared with PF (median OS: 43.2 *vs*. 22.3 months, *P* \< 0.05) [@B20]. Besides, a propensity score-matched analysis reported by Zhang P et al. indicated that CRT with DP induced better survival outcomes than PF (*P* = 0.009) [@B21]. In the present study, we also demonstrated that the DP regimen could produce encouraging results in ESCC, which is consistent with previous reports.

However, induction chemotherapy might have adverse effects on patient tolerance to subsequent concurrent CRT. In the phase II randomized trial of RTOG 0113, Ajani *et al.* reported that adding IC was associated with considerable morbidity (80% rate of grade 3 or 4 toxicities) [@B22]. Michel et al. reported that grade 3 or 4 toxicities were observed in 23.3% and 64.5% of patients, of which 57.1% and 58.1% were caused by hematoxicity during IC or CRT with cisplatin/irinotecan [@B6]. In the current study, grade 3-4 hematological toxicities were observed in 38.8% and 28.2% of patients receiving IC+CRT or CRT alone, respectively. The IC group had significantly higher proportions of grade 3-4 leucopenia than the CRT group (*P* = 0.048). However, although the risk of hematological toxicities in the IC group was higher than the CRT group, the toxicities were manageable and could be mitigated by preventive measures, suggesting that the combination of IC and CRT based on the DP regimen was well tolerated.

This study had several limitations. First, the study was limited by its retrospective nature and the fact it was conducted in a single institution. Second, the chemotherapy regimen included weekly and three-weekly regimens. However, the chemotherapy regimen did not affect the OS significantly in the univariate analysis, and thus had limited effects on our results.

Conclusions
===========

Our data demonstrated that a combination of IC and CRT might be a promising treatment strategy to further improve systemic control and survival of locally advanced ESCC. In addition, the results suggested that the IC responders have a better chemoradiotherapy effect, prolonged OS, improved locoregional control, and reduced distant metastasis. Prospective, randomized controlled trials are required to further confirm the role of IC.
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###### 

Patient and Tumor Characteristics

  ----------------------------------------------------------------------------------------------
  Characteristic                        Total\           IC+CRT\         CCRT\           *P*
                                        (*n* = 170), %   (*n* = 85), %   (*n* = 85), %   
  ------------------------------------- ---------------- --------------- --------------- -------
  **Sex**                                                                                

  Male                                  144 (84.7)       72 (84.7)       72(84.7)        1.000

  Female                                26 (15.3)        13 (15.3)       13 (15.3)       

  **Age (years)**                                                                        

  \<60                                  107 (62.9)       51 (60.0)       56 (65.9)       0.427

  ≥60                                   63 (37.1)        34 (40.0)       29 (34.1)       

  **Smoking**                                                                            

  Yes                                   132(77.6)        73(85.9)        59(69.4)        0.010

  No                                    38(22.4)         12(14.1)        26(30.6)        

  **Drinking**                                                                           

  Yes                                   129(75.9)        60(70.6)        69(81.2)        0.107

  No                                    41(24.1)         25(29.4)        16(18.8)        

  **Weight loss**                                                                        

  \<10%                                 139 (84.7)       71 (83.5)       68 (80.0)       0.692

  ≥10%                                  31 (15.3)        14 (16.5)       17 (20.0)       

  **ECOG PS**                                                                            

  0                                     28 (16.5)        14 (16.5)       14 (16.5)       1.000

  1-2                                   142 (83.5)       71 (83.5)       71 (83.5)       

  **Tumor location**                                                                     

  Upper third                           32(18.8)         16 (18.8)       16 (18.8)       1.000

  Middle third                          126 (74.1)       63 (74.1)       63 (74.1)       

  Lower third                           12 (7.1)         6 (7.1)         6 (7.1)         

  **Primary tumor length**                                                               

  \<6 cm                                68 (40.0)        29 (42.6)       39 (45.9)       0.117

  ≥6 cm                                 102 (60.0)       56 (65.9)       46 (54.1)       

  **Histologic grade**                                                                   

  Well/Moderately differentiated        109 (64.1)       56(65.9)        53 (62.4)       0.631

  Poorly differentiated                 61 (35.9)        29 (34.1)       32 (37.6)       

  **T stage**                                                                            

  T1-2                                  9 (5.3)          4 (4.7)         5 (5.9)         0.732

  T3-4                                  161 (94.7)       81 (95.3)       80 (94.1)       

  **N stage**                                                                            

  N0                                    14 (8.2)         6 (7.1)         8 (9.4)         0.577

  N1                                    156 (91.8)       79 (92.9)       77 (90.6)       

  **M stage**                                                                            

  M0                                    28 (16.5)        14 (16.5)       14(16.5)        1.000

  M1                                    142 (83.5)       71 (83.5)       71 (83.5)       

  **Pretreatment TNM stage**                                                             

  III                                   28 (16.5)        14 (16.5)       14(16.5)        1.000

  IV                                    142 (83.5)       71 (83.5)       71 (83.5)       

  **Radiotherapy technique**                                                             

  IMRT                                  126 (74.1)       67 (78.8)       59 (69.4)       0.161

  3DCRT                                 44(25.9)         18 (21.2)       26 (30.6)       

  **Concurrent chemotherapy regimen**                                                    

  Weekly                                78 (45.9)        44 (51.8)       34 (40.0)       0.124

  Three-weekly                          92 (54.1)        41 (48.2)       51(60.0)        
  ----------------------------------------------------------------------------------------------

*Abbreviations:* ECOG, Eastern Cooperative Oncology Group; PS, performance status.

###### 

Treatment-related toxicity (NCICTC 3.0)

  -----------------------------------------------------------------------
  Event of grade ≥3                IC+CRT\         CCRT\          *P*
                                   (*n* = 85), %   (*n* =85), %   
  -------------------------------- --------------- -------------- -------
  **Hematological toxicity**                                      

  Anemia                           1 (1.2)         2 (2.4)        1.000

  Leukopenia                       33 (38.8)       21 (24.7)      0.048

  Neutropenia                      28 (32.9)       20 (23.5)      0.173

  Thrombocytopenia                 8 (9.4)         5 (5.9)        0.387

  **Non-hematological toxicity**                                  

  Nausea/vomiting                  8 (9.4)         5 (5.9)        0.387

  Diarrhea                         2 (2.4)         2 (2.4)        1.000

  Esophagitis                      6 (7.1)         5 (5.9)        0.755

  Pneumonitis                      3 (3.5)         2 (2.4)        0.650

  Skin toxicity                    13 (15.3)       16 (18.8)      0.541

  Weight loss                      7 (8.2)         8 (9.4)        0.787

  Fatigue                          17 (20.0)       13 (15.3)      0.421
  -----------------------------------------------------------------------

Abbreviations: NCICTC3.0: National Cancer Institute Common Toxicity Criteria (version 3.0)

###### 

Univariate and multivariate analysis of prognostic factors related to survival (*n* = 170)

  Factor                                No.   Univariate   Multivariate                         
  ------------------------------------- ----- ------------ -------------- --------------------- -------
  **Sex**                                                                                       
  Male                                  144   27.8         0.982                                
  Female                                26    30.8                                              
  **Age (years)**                                                                               
  \<60                                  107   36.4         0.013          1.796 (1.216-2.652)   0.003
  ≥60                                   63    14.3                                              
  **Smoking**                                                                                   
  Yes                                   132   28.8         0.450                                
  No                                    38    26.3                                              
  **Drinking**                                                                                  
  Yes                                   129   27.9         0.308                                
  No                                    41    29.3                                              
  **Weight loss**                                                                               
  \<10%                                 139   27.3         0.482                                
  ≥10%                                  31    32.3                                              
  **Performance status**                                                                        
  0                                     28    28.6         0.641                                
  1-2                                   142   28.2                                              
  **Tumor location**                                                                            
  Upper third                           32    31.3         0.500                                
  Middle third                          126   28.6                                              
  Lower third                           12    16.7                                              
  **Primary tumor length**                                                                      
  \<6 cm                                68    30.8         0.863                                
  ≥6 cm                                 102   26.5                                              
  **Histologic grade**                                                                          
  Well/Moderately differentiated        109   27.5         0.398                                
  Poorly differentiated                 61    29.5                                              
  **Pretreatment TNM stage**                                                                    
  III                                   28    46.4         0.054          1.780 (1.047-3.025)   0.330
  IV                                    142   24.6                                              
  **Therapy regimen**                                                                           
  IC+CRT                                85    30.6         0.028          1.592 (1.092-2.322)   0.016
  CRT                                   85    25.9                                              
  **Radiotherapy technique**                                                                    
  IMRT                                  126   27.0         0.715                                
  3DCRT                                 44    31.8                                              
  **Concurrent chemotherapy regimen**                                                           
  Weekly                                78    32.1         0.231                                
  Three-weekly                          92    25.0                                              

*Abbreviations:* OS, overall survival; ECOG, Eastern Cooperative Oncology Group;
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